Results of a multicenter clinical trial found that adding the investigational adenoviral-based viral immunotherapy aglatimagene besadenovec (alglatimagene, CAN-2409) to standard radiation therapy ...
Novel prostate cancer treatment can reduce risk of disease progression by half, clinical trial shows
A Phase III clinical trial led by Neeraj Agarwal, MD, FASCO, senior director of clinical research at Huntsman Cancer Institute and professor of internal medicine at the University of Utah (the U), has ...
Aglatimagene is an investigational therapy that uses a modified virus to deliver a cancer-fighting gene into tumor cells.
New Jersey hospitals expand prostate cancer treatment with robotics, proton therapy and precision medicine innovations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results